A detailed history of Algert Global LLC transactions in Merus N.V. stock. As of the latest transaction made, Algert Global LLC holds 153,724 shares of MRUS stock, worth $7.16 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares
153,724
Previous 133,323 15.3%
Holding current value
$7.16 Million
Previous $7.89 Million 2.65%
% of portfolio
0.21%
Previous 0.26%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$47.19 - $58.84 $962,723 - $1.2 Million
20,401 Added 15.3%
153,724 $7.68 Million
Q2 2024

Aug 14, 2024

BUY
$39.81 - $60.2 $1.42 Million - $2.14 Million
35,549 Added 36.36%
133,323 $7.89 Million
Q1 2024

May 14, 2024

BUY
$28.03 - $51.82 $808,413 - $1.49 Million
28,841 Added 41.84%
97,774 $4.4 Million
Q4 2023

Feb 14, 2024

SELL
$20.06 - $28.66 $31,072 - $44,394
-1,549 Reduced 2.2%
68,933 $1.9 Million
Q3 2023

Nov 13, 2023

SELL
$20.13 - $27.29 $588,198 - $797,413
-29,220 Reduced 29.31%
70,482 $1.66 Million
Q2 2023

Aug 14, 2023

SELL
$18.33 - $27.18 $222,819 - $330,400
-12,156 Reduced 10.87%
99,702 $2.63 Million
Q1 2023

May 12, 2023

BUY
$14.25 - $20.5 $302,969 - $435,850
21,261 Added 23.47%
111,858 $2.06 Million
Q4 2022

Feb 13, 2023

BUY
$12.8 - $23.66 $498,944 - $922,266
38,980 Added 75.52%
90,597 $1.4 Million
Q3 2022

Nov 15, 2022

BUY
$18.64 - $28.93 $85,632 - $132,904
4,594 Added 9.77%
51,617 $1.03 Million
Q2 2022

Aug 15, 2022

BUY
$13.98 - $29.25 $59,135 - $123,727
4,230 Added 9.88%
47,023 $1.07 Million
Q1 2022

May 16, 2022

BUY
$23.58 - $30.91 $657,292 - $861,616
27,875 Added 186.85%
42,793 $1.13 Million
Q4 2021

Feb 14, 2022

SELL
$20.0 - $32.29 $19,000 - $30,675
-950 Reduced 5.99%
14,918 $474,000
Q3 2021

Nov 15, 2021

BUY
$16.48 - $27.23 $261,504 - $432,085
15,868 New
15,868 $349,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.14B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.